Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis

Diabetes Research and Clinical Practice

Volumn 88, Issue 1, 2010, Pages 111-116

  Kim, Soo Kyung ^a   Kim, Dae Jung ^b   Kim, Se Hwa ^c   Lee, Yeo Kyung ^a   Park, Seok Won ^a   Cho, Yong Wook ^a   Huh, Kap Bum ^d  

^a CHA University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Kwandong University College of Medicine   (South Korea)

^d 21st Century Hospital   (South Korea)

Author keywords

Alanine aminotransferase; Intima media thickness; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PREVALENCE; WAIST CIRCUMFERENCE;

ADULT; ALANINE TRANSAMINASE; CAROTID ARTERY DISEASES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS; TUNICA INTIMA; TUNICA MEDIA; WAIST CIRCUMFERENCE;

EID: 77649232967     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.01.003     Document Type: Article

References (28)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 (2002) 1221-1231
2. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
3. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 (2002) 373-379
4. Angelico F., Del Ben M., Conti R., Francioso S., Feole K., Fiorello S., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 90 (2005) 1578-1582
5. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
6. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30 (2007) 2119-2121
7. Arslan U., Türkoǧlu S., Balcioǧlu S., Tavil Y., Karakan T., and Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron. Artery Dis. 18 (2007) 433-436
8. Westerbacka J., Corner A., Tiikkainen M., Tamminen M., Vehkavaara S., Hakkinen A.M., et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47 (2004) 1360-1369
9. Schindhelm R.K., Dekker J.M., Nijpels G., Bouter L.M., Stehouwer C.D., Heine R.J., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007) 391-396
10. Oh S.Y., Cho Y.K., Kang M.S., Yoo T.W., Park J.H., Kim H.J., et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 55 (2006) 1604-1609
11. Patel D.A., Srinivasan S.R., Xu J.H., Chen W., and Berenson G.S. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 56 (2007) 792-798
12. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23 (2006) 469-480
13. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005) 473-480
14. Targher G., Bertolini L., Padovani R., Zenari L., Zoppini G., and Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 (2004) 2498-2500
15. Brea A., Mosquera D., Martín E., Arizti A., Cordero J.L., and Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1045-1050
16. Fracanzani A.L., Burdick L., Raselli S., Pedotti P., Grigore L., Santorelli G., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am. J. Med. 121 (2008) 72-78
17. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., Ulmer H., et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112 (2005) 2130-2137
18. Lee D.S., Evans J.C., Robins S.J., Wilson P.W., Albano I., Fox C.S., et al. Gamma glutamyl-transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 127-133
19. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
20. Fracanzani A.L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48 (2008) 792-798
21. Kim H.C., Choi K.S., Jang Y.H., Shin H.W., and Kim D.J. Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. Yonsei Med. J. 47 (2006) 542-550
22. Kong A.P., Choi K.C., Cockram C.S., Ho C.S., Chan M.H., Ozaki R., et al. Independent associations of alanine aminotransferase (ALT) levels with cardiovascular risk factor clustering in Chinese adolescents. J. Hepatol. 49 (2008) 115-122
23. Penn R., and Worthington D.J. Is serum gamma-glutamyltransferase a misleading test?. Br. Med. J. 286 (1983) 531-535
24. Strasak A.M., Kelleher C.C., Klenk J., Brant L.J., Ruttmann E., Rapp K., et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1857-1865
25. Pompella A., Emdin M., Passino C., and Paolicchi A. The significance of serum gamma-glutamyltransferase in cardiovascular diseases. Clin. Chem. Lab. Med. 42 (2004) 1085-1091
26. Lee D.H., Silventoinen K., Hu G., Jacobs Jr. D.R., Jousilahti P., Sundvall J., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28838 middle-aged men and women. Eur. Heart J. 27 (2006) 2170-2176
27. Lee D.H., Ha M.H., Kim J.H., Christiani D.C., Gross M.D., Steffes M., et al. Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia 46 (2003) 359-364
28. Lee S.Y., Park H.S., Kim D.J., Han J.H., Kim S.M., Cho G.J., et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res. Clin. Pract. 75 (2007) 72-80